Form 13-F position report

ADC THERAPEUTICS SA

Reported by ALLIANCEBERNSTEIN L P

ADCT CUSIP H0036K147 Manager CIK 0001109448

First reported at 22,020 shares this quarter.

New
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 22,020 Quarter-end amount reported
Reported value $69,583 Fair value at quarter end
Consecutive quarters held 1 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 56716000
2022-03-31 43439000
2022-06-30 23545000
2022-09-30 14051000
2022-12-31 10847831
2023-03-31 0
2024-06-30 69583
2024-09-30 69363
2024-12-31 43820
2025-03-31 31048
2025-06-30 132901
2025-09-30 198360
2025-12-31 147731
2026-03-31 147731
2026-06-30 406763
2026-09-30 132333

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for ADC THERAPEUTICS SA held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 108,470 0 (0.0%) < 0.01% $132,333 2026-11-16
Q2 2026 Added 108,470 +66,620 (159.2%) < 0.01% $406,763 2026-08-14
Q1 2026 Unchanged 41,850 0 (0.0%) < 0.01% $147,731 2026-05-15
Q4 2025 Reduced 41,850 -7,740 (-15.6%) < 0.01% $147,731 2026-02-17
Q3 2025 Unchanged 49,590 0 (0.0%) < 0.01% $198,360 2025-11-14
Q2 2025 Added 49,590 +27,570 (125.2%) < 0.01% $132,901 2025-08-14
Q1 2025 Unchanged 22,020 0 (0.0%) < 0.01% $31,048 2025-05-15
Q4 2024 Unchanged 22,020 0 (0.0%) < 0.01% $43,820 2025-02-12
Q3 2024 Unchanged 22,020 0 (0.0%) < 0.01% $69,363 2024-11-14
Q2 2024 New 22,020 +22,020 (0.0%) < 0.01% $69,583 2024-08-14
Q1 2023 Reduced 0 -2,824,956 (-100.0%) 0 $0 2023-05-15
Q4 2022 Reduced 2,824,956 -90,204 (-3.1%) < 0.01% $10,847,831 2023-02-15
Q3 2022 Reduced 2,915,160 -46,464 (-1.6%) < 0.01% $14,051,000 2022-11-15
Q2 2022 Added 2,961,624 +4,568 (0.2%) 0.01% $23,545,000 2022-08-15
Q1 2022 Added 2,957,056 +149,333 (5.3%) 0.02% $43,439,000 2022-05-13
Q4 2021 Added 2,807,723 +153,506 (5.8%) 0.02% $56,716,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

83 managers reported ADC THERAPEUTICS SA for Q2 2024.

Managers reporting ADC THERAPEUTICS SA in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Redmile Group LLC Unchanged 15,269,217 0 2.92% $48,250,726 17 qtrs
Prosight Management LP Added 9,570,000 +2,519,700 9.04% $30,241,200 8 qtrs
ORBIMED ADVISORS LLC New 4,316,824 +4,316,824 0.27% $13,641,164 1 qtr
BlackRock Inc New 3,554,742 +3,554,742 < 0.01% $11,232,984 1 qtr
MORGAN STANLEY Added 2,965,229 +244,834 < 0.01% $9,370,123 17 qtrs
SILVERARC CAPITAL MANAGEMENT LLC Added 1,768,770 +1,267,548 1.32% $5,589,313 2 qtrs
The Goldman Sachs Group Inc Reduced 1,524,717 -15,792 < 0.01% $4,818,106 8 qtrs
PLATINUM INVESTMENT MANAGEMENT LTD New 1,296,153 +1,296,153 0.17% $4,095,843 1 qtr
Bank of America Corporation Added 1,216,418 +22,571 < 0.01% $3,843,881 17 qtrs
Artal Group S A New 1,018,461 +1,018,461 0.08% $3,218,337 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
SHS

Voting authority reported

Sole
22,020
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.